FDA Could Answer "Clarifying" Questions, But Only For Firms Without Approved Product
Executive Summary
The drug industry is not only worried about vulnerable patients, it's worried about vulnerable companies.
You may also be interested in...
PDUFA V: Emerging Sponsor Communication Issue Resolved And Expanded
FDA and industry plan to create more staff to help deal with simple and clarifying questions from emerging and experienced sponsors during the application review process as part of PDUFA V.
PDUFA V: Emerging Sponsor Communication Issue Resolved And Expanded
FDA and industry plan to create more staff to help deal with simple and clarifying questions from emerging and experienced sponsors during the application review process as part of PDUFA V.
PDUFA V: FDA Relaxes Pre-Submission Meeting Requirement
Sponsors may have negotiated a four-month reprieve for the required pre-submission meeting in the proposed new application review system expected to be implemented with PDUFA V.